MOONLAKE IMMUNOTHERAPEUTICS Comprehensive Income
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) reported Comprehensive Income of -$61.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-10
- MOONLAKE IMMUNOTHERAPEUTICS comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$61.50M.
- MOONLAKE IMMUNOTHERAPEUTICS comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$69.99M.
- MOONLAKE IMMUNOTHERAPEUTICS comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$62.11M.
- MOONLAKE IMMUNOTHERAPEUTICS comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$69.97M.
- MOONLAKE IMMUNOTHERAPEUTICS comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$231.73M.
- MOONLAKE IMMUNOTHERAPEUTICS comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$116.38M.
- MOONLAKE IMMUNOTHERAPEUTICS comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$34.51M.
- MOONLAKE IMMUNOTHERAPEUTICS comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$49.44M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 10 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$61.50M 10-Q · filed 2026-08-10 | -$131.49M 10-Q · filed 2026-08-10 | -$193.59M derived: sum of 3 quarters · filed 2026-08-10 | -$263.57M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2026-03-31 | -$69.99M 10-Q · filed 2026-05-11 | -$132.10M derived: sum of 2 quarters · filed 2026-05-11 | -$202.07M derived: sum of 3 quarters · filed 2026-05-11 | -$259.16M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-12-31 | -$62.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$132.08M derived: sum of 2 quarters · filed 2026-02-25 | -$189.17M derived: sum of 3 quarters · filed 2026-08-10 | -$231.73M 10-K · filed 2026-02-25 | |||||
| 2025-09-30 | -$69.97M 10-Q · filed 2025-11-05 | -$127.06M derived: sum of 2 quarters · filed 2026-08-10 | -$169.62M 10-Q · filed 2025-11-05 | -$213.06M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-06-30 | -$57.09M 10-Q · filed 2026-08-10 | -$99.65M 10-Q · filed 2026-08-10 | -$143.09M derived: sum of 3 quarters · filed 2026-08-10 | -$178.92M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-03-31 | -$42.56M 10-Q · filed 2026-05-11 | -$86.01M derived: sum of 2 quarters · filed 2026-05-11 | -$121.83M derived: sum of 3 quarters · filed 2026-05-11 | -$145.53M derived: sum of 4 quarters · filed 2026-05-11 | |||||
| 2024-12-31 | -$43.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$79.27M derived: sum of 2 quarters · filed 2026-02-25 | -$102.97M derived: sum of 3 quarters · filed 2026-02-25 | -$116.38M 10-K · filed 2026-02-25 | -$116.38M 10-K · filed 2025-02-26 | ||||
| 2024-09-30 | -$35.82M 10-Q · filed 2025-11-05 | -$35.82M 10-Q · filed 2024-11-07 | -$59.53M derived: sum of 2 quarters · filed 2025-11-05 | -$72.94M 10-Q · filed 2025-11-05 | -$72.94M 10-Q · filed 2024-11-07 | -$81.36M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-06-30 | -$23.70M 10-Q · filed 2025-08-05 | -$23.70M 10-Q · filed 2024-08-07 | -$37.12M 10-Q · filed 2025-08-05 | -$37.12M 10-Q · filed 2024-08-07 | -$45.53M derived: sum of 3 quarters · filed 2026-02-25 | -$52.12M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-03-31 | -$13.42M 10-Q · filed 2025-05-12 | -$13.42M 10-Q · filed 2024-05-07 | -$21.83M derived: sum of 2 quarters · filed 2026-02-25 | -$28.42M derived: sum of 3 quarters · filed 2026-02-25 | -$38.91M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | -$8.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$15.01M derived: sum of 2 quarters · filed 2026-02-25 | -$25.49M derived: sum of 3 quarters · filed 2026-02-25 | -$34.51M 10-K · filed 2026-02-25 | -$34.51M 10-K · filed 2024-02-29 | ||||
| 2023-09-30 | -$6.59M 10-Q · filed 2024-11-07 | -$17.08M derived: sum of 2 quarters · filed 2024-11-07 | -$26.10M 10-Q · filed 2024-11-07 | -$43.03M derived: sum of 4 quarters · filed 2025-02-26 | |||||
| 2023-06-30 | -$10.49M 10-Q · filed 2024-08-07 | -$19.51M 10-Q · filed 2024-08-07 | -$36.44M derived: sum of 3 quarters · filed 2025-02-26 | -$46.43M derived: sum of 4 quarters · filed 2025-02-26 | |||||
| 2023-03-31 | -$9.02M 10-Q · filed 2024-05-07 | -$25.95M derived: sum of 2 quarters · filed 2025-02-26 | -$35.95M derived: sum of 3 quarters · filed 2025-02-26 | -$48.00M derived: sum of 4 quarters · filed 2025-02-26 | |||||
| 2022-12-31 | -$16.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$26.93M derived: sum of 2 quarters · filed 2025-02-26 | -$38.98M derived: sum of 3 quarters · filed 2025-02-26 | -$49.44M 10-K · filed 2025-02-26 | |||||
| 2022-09-30 | -$10.00M 10-Q · filed 2023-11-14 | -$22.05M derived: sum of 2 quarters · filed 2023-11-14 | -$32.51M 10-Q · filed 2023-11-14 | ||||||
| 2022-06-30 | -$12.05M 10-Q · filed 2023-08-10 | -$22.51M 10-Q · filed 2023-08-10 | |||||||
| 2022-03-31 | -$15.61M 10-Q · filed 2023-05-11 | ||||||||
| 2021-12-31 | -$53.81M 10-K · filed 2023-03-20 | ||||||||
| 2021-09-30 | -$6.29M 10-Q · filed 2022-11-14 | -$38.97M derived: sum of 2 quarters · filed 2022-11-14 | -$39.33M 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | -$32.69M 10-Q · filed 2022-08-12 | -$33.04M 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |